Tirzepatide currently being a dual GLP-1 and GIP agonist, it is actually advised that the GIP component of twin agonism may very well be responsible for the additional profit, specified the opportunity advantage of GIP receptor agonism on peripheral insulin sensitization. As a result, tirzepatide was more effective than dulaglutide in cutting down